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Abstract  
 
Purpose 
This commentary accompanies Clare et al’s study investigating psychotropic drug prescribing 
for adults with intellectual disability who were referred to specialist community learning 
disability teams in the east of England. The aim is to explore some of the background to 
psychotropic drug prescribing for people with intellectual disability, review important 
contextual factors involved that influence prescribing decisions, and consider how we might 
make the best use of psychotropic drugs in this group.  
 
Design/methodology/approach 
Narrative summary and opinion, supported by reference to recent research literature.  
 
Findings 
Psychotropic drug use for people with intellectual disability is complex, not least because of 
the lack of research evidence that exists on the topic. Psychotropic drugs can be an important 
part of treatment for people with mental illness but further research is needed to support 
prescribing for challenging behaviour. Medication optimisation is a framework within which 
individual preferences and values are considered alongside the evidence-base and clinical 
judgement in order to inform safe, effective, and collaborative management decisions. 
 
Practical implications 
Prescribing decisions should be individualised and reviewed regularly, incorporating evidence 
from patients and carers. Improving the use of psychotropic medication requires concerted 
action, adequate social support, and the provision of alternative, non-pharmacological 
interventions that are acceptable and effective.  
 
Originality/value 
 This paper reviews some of the current concerns about the use of psychotropic drugs and 
opens up new avenues of discussion.   
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 Optimising psychotropic medication use 
 
The prescribing of psychotropic medication to people with intellectual disability continues to 
attract interest and be an ongoing source of controversy. The paper by Isabel Clare and 
colleagues in this edition of the journal is a relatively small-scale investigation of psychotropic 
medication prescribing in a sample of adults referred to multi-disciplinary intellectual 
disability services in the east of England. The paper adds evidence from community secondary 
care to recent research on psychotropic prescribing which has drawn on large electronic 
primary care databases (Sheehan et al., 2015). The high rate of psychotropic prescribing found 
by Clare et al. is not a surprise, given what we already know on the subject and the fact that 
individuals referred to secondary care services will often have complex mental and 
behavioural presentations. Similarly, the relatively large proportion of the sample who were 
prescribed psychotropic drugs in the absence of an underlying diagnosis of mental illness is 
consistent with previous data and may suggest off-license use of medication, in some cases 
(Paton et al., 2016). 
 
Yet again, this study provokes questions about the place of psychotropic medications in the 
treatment of adults with intellectual disability. Whereas few would disagree that psychotropic 
medication is indicated in the management of diagnosed mental disorder there is, in fact, 
relatively little evidence for the efficacy and safety of these drugs specifically in people with 
intellectual disability. Knowledge of the effects of psychotropic drugs is extrapolated from 
evidence of studies of their use in the non-intellectually disabled population, which may have 
limited external validity. Indeed, there are reasons to believe that the pharmacodynamics of 
psychotropic drugs are different in people with intellectual disability, possibly owing to 
interaction with pre-existing cognitive deficits and co-morbid conditions. For example, we 
recently showed that people with intellectual disability are more susceptible to centrally-
mediated movement side-effects of antipsychotic drugs, such as akathisia and Parkinsonism 
(Sheehan et al., 2017). In our study, neuroleptic malignant syndrome, a rare but potentially-
fatal side-effect of antipsychotic drugs was also much more common in people with 
intellectual disability. Risk factors, the presentation of mental illness and its natural history 
 may all be different in people with intellectual disability and not only make accurate diagnosis 
more difficult but also potentially influence treatment response.  
 
People with intellectual disability are under-represented in medical research and are 
routinely excluded from clinical studies, either explicitly in study protocols, or indirectly by 
virtue of trial processes and procedures that disadvantage those with cognitive deficits. 
Researchers might be deterred by assumptions about the ability of people with intellectual 
disability to provide informed consent and perceived obstacles in gaining ethical approval for 
recruitment of participants who lack capacity (Goldsmith and Skirton, 2015). Even studies 
designed for participants with intellectual disability can face problems recruiting adequate 
numbers, as clinicians might be reluctant to nominate those who are potentially eligible.  
 
Whilst the use of psychotropic medication for mental illness in people with intellectual 
disability is generally not disputed, the use of medication for challenging behaviour is more 
contentious. Challenging behaviour does not have an obvious equivalent in the non-
intellectually disabled population and there is little evidence that can be transferred from 
other groups. The antipsychotic drugs risperidone and aripiprazole show some benefit in the 
short-term management of challenging behaviour in children (McQuire et al., 2015) but 
evidence for their use for challenging behaviour in adults with intellectual disability is 
inconclusive, at best (Deb, 2014). Psychotropic prescribing is not without risks; as mentioned 
above, adverse side-effects are common and may negatively impact wellbeing (Koch et al., 
2015). On this basis, national and international best practice consensus guidelines for the 
management of challenging behaviour favour psychosocial interventions (NICE, 2015a). 
Guidelines recognise only a limited place for antipsychotic drugs in the management of 
challenging behaviour in the absence of a diagnosis of mental illness where, for example, the 
risk of harm is severe and alternative interventions have failed. Causes of challenging 
behaviour are multiple and varied, and most often there will not be a single explanation. 
Psychotropic medication should be used alongside psychosocial interventions with the focus 
remaining on determining and addressing the cause of the behaviour, rather than merely 
suppressing it by sedating the individual.  
 
 A small number of cases of challenging behaviour may have biological underpinnings which 
are legitimate targets for pharmacological manipulation. The opiate hypothesis of self-injury 
holds that chronically high circulating levels of endogenous opiates or opiate receptor 
dysregulation reduces sensitivity to pain and the self-injury then becomes a form of sensory 
stimulation. Self-injury may then be reinforced by the pleasurable, euphoric-like effects 
induced by the release of endogenous opiates (Sandman and Hetrick, 1995). The opiate 
hypothesis thus neatly indicates rational management with opiate receptor blockers, such as 
naltrexone, to attenuate self-injury. However, formal research evidence for the benefit of 
opiate antagonists used in this context is relatively weak (Rana et al., 2013) suggesting that 
other factors must also be important. 
 
Behavioural phenotypes, in which genetic or chromosomal conditions are associated with a 
characteristic pattern of behaviour and neurodevelopmental profile, also seem to suggest an 
important role of individual constitutional factors in the development and expression of 
challenging behaviour. However, even where the genetic and molecular basis of the disorder 
is well-characterised, the pathway to challenging behaviour is often tangential. For example, 
although the genetic basis of Lesch-Nyhan syndrome and the subsequent metabolic 
abnormality have been known for several decades, this has not translated to effective 
treatments for the developmental and behavioural aspects of the disorder and the severe 
self-injury that characterises this syndrome has been shown to be mediated by environmental 
factors (Hall et al., 2001). 
 
Aggression is the most prevalent type of challenging behaviour in people with intellectual 
disability and is a common reason for referral to clinical services (Emerson et al., 2001). The 
neurobiological underpinnings of aggression have been studied in detail; aberrant conduction 
in central dopaminergic, serotonergic, and GABA pathways have all been implicated (Willner, 
2015). However the neurobiological system is complex and interdependent and targeted 
pharmacological treatments for aggression have largely been unsuccessful.  
 
Any biological explanations for challenging behaviour are clearly, therefore, only one part of 
a complex picture. They may contribute to the formulation of certain cases of challenging 
behaviour but do not negate the social dimensions of behavioural disturbance. Challenging 
 behaviour as a concept necessarily involves an interaction with the environment and 
management strategies that focus only on the individual cannot ever be wholly successful. 
Effective intervention depends on the implementation of broader strategies that complement 
one another and consider psychological, social and environmental determinants, as well as 
potential biological and medical causes.  
 
Translating new scientific advances to everyday care will take time and we still need much 
more research before the promise of targeted drug therapy may be realised for many people 
with intellectual disability. More work is needed to explore the topographies of challenging 
behaviour and subgroups of people who may benefit from psychotropic medication. In the 
meantime, we must ensure that psychotropics are used pragmatically, whether for mental 
illness or challenging behaviour. Medicines optimisation is an approach to prescribing that 
aims to maximise benefit and minimise harm of medication, with a focus on patient 
experience and outcome (NICE, 2015b). Embedded within this is a central role for the values 
and preferences of patients (and others who may support or advocate for them) which are 
considered alongside the scientific evidence base and clinical experience as part of a process 
of shared decision making. Thus, the concept extends beyond the practical issues of 
prescribing, such as those of drug administration and potential interactions, that must also 
be considered (Trollor et al., 2016).  
 
Given the relative lack of evidence, Santosh and Baird suggest treating each case of 
prescribing for people with intellectual disability as a single case study (Santosh and Baird, 
1999). Determining the risks and benefits of medication is contingent on access to good 
quality data. Positive effects of medication on symptoms or functioning should be recorded 
and plotted against unwanted or adverse effects, preferably using validated scales 
(Ramerman et al., 2017). People with intellectual disability often have reduced health literacy 
and are less likely to recognise or report adverse events and a combination of collateral 
information, behavioural observations, and clinical assessment are essential in judging the 
overall impact of a medication. Whilst the paper by Clare and colleagues did not find that 
polypharmacy or prescription of high doses of antipsychotics were common, other research 
has shown this to be the case (Bowring et al., 2017) and psychotropic medication is frequently 
used over extended periods of time (McGillivray and McCabe, 2006). Clinicians and carers 
 need to be empowered and prepared to take a critical stance with respect to long-term use 
of medication. Physical health monitoring, necessary to reduce the risks of iatrogenic harm, 
is inadequate in people with intellectual disability who are prescribed psychotropic 
medication (Paton et al., 2016) and requires close collaboration between primary and 
secondary care.  
 
To improve, and potentially reduce, psychotropic prescribing for challenging behaviour we 
must recognise the non-clinical influences and competing demands that can impact 
prescribing decisions. Various upstream factors, such as carer attributions for a behaviour, 
can heavily influence staff response (Hastings and Remington, 1994). Prescribing does not 
occur in isolation from other management decisions; psychiatrists express a strong 
preference for non-medication based intervention as first line management in challenging 
behaviour in the absence of mental illness (Unwin and Deb, 2008) but may find themselves 
with few other options where alternative psychosocial strategies are not readily available. 
Provision of adequate care and support has been highlighted as a factor likely to increase the 
chances that physicians will attempt to reduce or discontinue antipsychotic drugs used for 
behaviour (Kuijper and Hoekstra, 2017). Even when medications used for behaviour are 
reduced, the success or otherwise of withdrawal depends largely on setting rather than 
individual factors, such as availability of trained support staff (Ahmed et al., 2000). 
 
Conclusions 
 
Psychotropic medication is an important part of treatment for many people with intellectual 
disability who have co-morbid mental illness, and might be helpful in select cases of 
challenging behaviour. As the evidence base for use of psychotropic drugs in people with 
intellectual disability is limited, prescribing decisions must be made on a case-by-case basis, 
in collaboration with the person with intellectual disability and those whom they trust to 
support them. Owing to the likely increased rate of side-effects in this group and the potential 
for atypical and idiosyncratic reactions, medication should be reviewed regularly with 
reference to target symptoms and valid sources of data.    
 
 There is now reasonably good evidence that suggests over-use of psychotropic medication in 
people with intellectual disability. Improving prescribing requires a nuanced approach that 
recognises the relationships between psychotropic drug use and the wider health and social 
care environment. It is important that we do not disadvantage people who may stand to 
benefit from psychotropic drugs. Applying a framework of medication optimisation could 
promote shared decision making and ensure the best use of psychotropic medication as part 
of holistic, person-centred treatment.  
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